<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28726764</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Fluorination of Naturally Occurring N&#x2076;-Benzyladenosine Remarkably Increased Its Antiviral Activity and Selectivity.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1219</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules22071219</ELocationID><Abstract><AbstractText>Recently, we demonstrated that the natural cytokinin nucleosides <i>N</i>&#x2076;-isopentenyladenosine (<b>iPR</b>) and <i>N</i>&#x2076;-benzyladenosine (<b>BAPR</b>) exert a potent and selective antiviral effect on the replication of human enterovirus 71. In order to further characterize the antiviral profile of this class of compounds, we generated a series of fluorinated derivatives of <b>BAPR</b> and evaluated their activity on the replication of human enterovirus 71 in a cytopathic effect (CPE) reduction assay. The monofluorination of the <b>BAPR</b>-phenyl group changed the selectivity index (SI) slightly because of the concomitant high cell toxicity. Interestingly, the incorporation of a second fluorine atom resulted in a dramatic improvement of selectivity. Moreover, <i>N</i>&#x2076;-trifluoromethylbenzyladenosines derivatives (<b>9</b>-<b>11</b>) exhibited also a very interesting profile, with low cytotoxicity observed. In particular, the analogue <i>N</i>&#x2076;-(3-trifluoromethylbenzyl)-adenosine (<b>10</b>) with a four-fold gain in potency as compared to <b>BAPR</b> and the best SI in the class represents a promising candidate for further development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oslovsky</LastName><ForeName>Vladimir E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia. vladimiroslovsky@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drenichev</LastName><ForeName>Mikhail S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia. mdrenichev@mail.ru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory for Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven-University of Leuven, Minderbroedersstraat 10, Leuven 3000, Belgium. liang.sun@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurochkin</LastName><ForeName>Nikolay N</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia. nikola.76@mail.ru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunetsky</LastName><ForeName>Vladislav E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia. kunvladea@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirabelli</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory for Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven-University of Leuven, Minderbroedersstraat 10, Leuven 3000, Belgium. carmen.mirabelli@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory for Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven-University of Leuven, Minderbroedersstraat 10, Leuven 3000, Belgium. johan.neyts@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyssen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory for Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven-University of Leuven, Minderbroedersstraat 10, Leuven 3000, Belgium. pieter.leyssen@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikhailov</LastName><ForeName>Sergey N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia. smikh@eimb.ru.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054879" MajorTopicYN="N">Halogenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SAR</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">fluorinated N6-benzyladenosines</Keyword><Keyword MajorTopicYN="N">synthesis and antiviral activity</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28726764</ArticleId><ArticleId IdType="pmc">PMC6152005</ArticleId><ArticleId IdType="doi">10.3390/molecules22071219</ArticleId><ArticleId IdType="pii">molecules22071219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Butler M.S., Robertson A.A., Cooper M.A. Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 2014;31:1612&#x2013;1661. doi: 10.1039/C4NP00064A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4NP00064A</ArticleId><ArticleId IdType="pubmed">25204227</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M.E. Design and synthesis of analogues of natural products. Org. Biomol. Chem. 2015;13:5302&#x2013;5343. doi: 10.1039/C5OB00169B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5OB00169B</ArticleId><ArticleId IdType="pubmed">25829247</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenichev M.S., Oslovsky V.E., Mikhailov S.N. Cytokinin nucleosides-natural compounds with a unique spectrum of biological activity. Curr. Top. Med. Chem. 2016;16:2562&#x2013;2576. doi: 10.2174/1568026616666160414123717.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026616666160414123717</ArticleId><ArticleId IdType="pubmed">27086793</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailov S.N., Scotti L., Singla R.K., Scotti M.T. Perspectives in Medicinal Chemistry. Curr. Top. Med. Chem. 2016;16:2725&#x2013;2726. doi: 10.2174/156802661625160816180839.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156802661625160816180839</ArticleId><ArticleId IdType="pubmed">27549858</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E., Li G. Approved Antiviral Drugs over the Past 50 Years. Clin. Microbiol. Rev. 2016;29:695&#x2013;747. doi: 10.1128/CMR.00102-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00102-15</ArticleId><ArticleId IdType="pmc">PMC4978613</ArticleId><ArticleId IdType="pubmed">27281742</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozenski J., Crain P.F., McCloskey J.A. The RNA Modification Database: 1999 update. Nucleic Acids Res. 1999;27:196&#x2013;197. doi: 10.1093/nar/27.1.196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/27.1.196</ArticleId><ArticleId IdType="pmc">PMC148133</ArticleId><ArticleId IdType="pubmed">9847178</ArticleId></ArticleIdList></Reference><Reference><Citation>Agris P., Crain P.F., Rozenski J., Fabris D., Vendeix F.A.P.  The RNA Institute;  [(accessed on 23 June 2017)]. The RNA Modification Database. Available online:  http://mods.rna.albany.edu.</Citation></Reference><Reference><Citation>Ernst D., Sch&#xe1;fer W., Oesterhelt D. Isolation and identification of a new, naturally occurring cytokinin (6-benzylaminopurineriboside) from an anise cell culture (Pimpinella anisum L.) Planta. 1983;159:222&#x2013;225. doi: 10.1007/BF00397528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00397528</ArticleId><ArticleId IdType="pubmed">24258171</ArticleId></ArticleIdList></Reference><Reference><Citation>Horgan R., Hewett E.W., Horgan J.M., Purse J., Wareing P.F. A new cytokinin from Populus x robusta. Phytochemistry. 1975;14:1005&#x2013;1008. doi: 10.1016/0031-9422(75)85176-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0031-9422(75)85176-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge L., Yong J.W.H., Goh N.K., Chia L.S., Tan S.N., Ong E.S. Identification of kinetin and kinetin riboside in coconut (Cocos nucifera L.) water using a combined approach of liquid chromatography-tandem mass spectrometry, high performance liquid chromatography and gel electrophoresis. J. Chromatogr. B. 2005;829:26&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16216563</ArticleId></ArticleIdList></Reference><Reference><Citation>Young D.C., Layre E., Pan S.-J., Tapley A., Adamson J., Seshadri C., Wu Z., Buter J., Minnaard A.J., Coscolla M., et al. In vivo biosynthesis of terpene nucleosides provides unique chemical markers of Mycobacterium tuberculosis infection. Chem. Biol. 2015;22:516&#x2013;526. doi: 10.1016/j.chembiol.2015.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2015.03.015</ArticleId><ArticleId IdType="pmc">PMC4432472</ArticleId><ArticleId IdType="pubmed">25910243</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 2008;89:2518&#x2013;2530. doi: 10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., Lin T.Y., Hsu K.H., Huang Y.C., Lin K.L., Hsueh C., Shih S.R., Ning H.C., Hwang M.S., Wang H.S., et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999;354:1682&#x2013;1686. doi: 10.1016/S0140-6736(99)04434-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K.T., Munisamy B., Ong K.C., Kojima H., Noriyo N., Chua K.B., Ong B.B., Nagashima K. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J. Neuropathol. Exp. Neurol. 2008;67:162&#x2013;169. doi: 10.1097/nen.0b013e318163a990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e318163a990</ArticleId><ArticleId IdType="pubmed">18219253</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., et al. Hand, foot, and mouth disease in China, 2008-12: An epidemiological study. Lancet Infect. Dis. 2014;14:308&#x2013;318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip C.C.Y., Lau S.K.P., Woo P.C.Y., Yuen K.-Y. Human enterovirus 71 epidemics: What&#x2019;s next? Emerg. Health Threats J. 2013;6:e19780. doi: 10.3402/ehtj.v6i0.19780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ehtj.v6i0.19780</ArticleId><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunaseelan S., Chu J.J.H. Identifying novel antiviral targets against enterovirus 71: Where are we? Future Virol. 2017;12:171&#x2013;191. doi: 10.2217/fvl-2016-0144.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2016-0144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Lyoo H., van der Schaar H.M., Strating J.R., van Kuppeveld F.J. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. Curr. Opin. Virol. 2017;24:25&#x2013;30. doi: 10.1016/j.coviro.2017.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2017.03.009</ArticleId><ArticleId IdType="pmc">PMC7172203</ArticleId><ArticleId IdType="pubmed">28411509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tararov V.I., Tijsma A., Kolyachkina S.V., Oslovsky V.E., Neyts J., Drenichev M.S., Leyssen P., Mikhailov S.N. Chemical modification of the plant isoprenoid cytokinin N6-isopentenyladenosine yields a selective inhibitor of human enterovirus 71 replication. Eur. J. Med. Chem. 2015;90:406&#x2013;413. doi: 10.1016/j.ejmech.2014.11.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2014.11.048</ArticleId><ArticleId IdType="pubmed">25461889</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenichev M.S., Oslovsky V.E., Sun L., Tijsma A., Kurochkin N.N., Tararov V.I., Chizhov A.O., Neyts J., Pannecouque C., Leyssen P., et al. The length and structure of the linker in N6-benzyladenosine derivatives affects the antiviral potency against enterovirus 71. Eur. J. Med. Chem. 2016;111:84&#x2013;94. doi: 10.1016/j.ejmech.2016.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.01.036</ArticleId><ArticleId IdType="pubmed">26854380</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller K., Faeh C., Diederich F. Fluorine in pharmaceuticals: Looking beyond intuition. Science. 2007;317:1881&#x2013;1886. doi: 10.1126/science.1131943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1131943</ArticleId><ArticleId IdType="pubmed">17901324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., S&#xe1;nchez-Rosell&#xf3; M., Ace&#xf1;a J.L., del Pozo C., Sorochinsky A.E., Fustero S., Soloshonok V.A., Liu H. Fluorine in pharmaceutical industry: Fluorine-containing drugs introduced to the market in the last decade (2001&#x2013;2011) Chem. Rev. 2014;114:2432&#x2013;2506. doi: 10.1021/cr4002879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr4002879</ArticleId><ArticleId IdType="pubmed">24299176</ArticleId></ArticleIdList></Reference><Reference><Citation>Tararov V.I., Kolyachkina S.V., Alexeev C.S., Mikhailov S.N. N6-acetyl-2&#x2032;,3&#x2032;,5&#x2032;-tri-O-acetyladenosine, a convenient, missed out substrate for regioselective N6-alkylations. Synthesis. 2011:2483&#x2013;2489. doi: 10.1055/s-0030-1260090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0030-1260090</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolyachkina S.V., Tararov V.I., Alexeev C.S., Krivosheev D.M., Romanov G.A., Stepanova E.V., Solomko E.S., Inshakov A.N., Mikhailov S.N. N6-Substituted adenosines. Cytokinin and antitumor activities. Collect. Czech. Chem. Commun. 2011;76:1361&#x2013;1378. doi: 10.1135/cccc2011114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1135/cccc2011114</ArticleId></ArticleIdList></Reference><Reference><Citation>Dole&#x17e;al K., Popa I., Hauserov&#xe1; E., S&#x1e55;&#x131;chal L., Chakrabarty K., Nov&#xe1;k O., Kry&#x161;tof V., Voller J., Holub J., Strnad M. Preparation, biological activity and endogenous occurrence of N6-benzyladenosines. Bioorg. Med. Chem. 2007;15:3737&#x2013;3747. doi: 10.1016/j.bmc.2007.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2007.03.038</ArticleId><ArticleId IdType="pubmed">17418578</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleysher M.H., Bloch A., Hakala M.T., Nichol C.A. Synthesis and biological activity of some new N6-substituted purine nucleosides. J. Med. Chem. 1969;12:1056&#x2013;1061. doi: 10.1021/jm00306a021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00306a021</ArticleId><ArticleId IdType="pubmed">4900616</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x17d;emli&#x10d;ka J., Owens J. 6-Chloro-9-&#x3b2;-d-ribofuranosylpurine. A versatile intermediate in the synthesis of purine ribonucleosides. In: Townsend L.B., Tipson R.S., editors. Nucleic Acid Chemistry, Part 2. Wiley; New York, NY, USA: 1978. pp. 611&#x2013;614.</Citation></Reference><Reference><Citation>Marek R., Sklen&#xe0;&#x159; V. NMR studies of purines. Annu. Rep. NMR Spectrosc. 2004;54:201&#x2013;242.</Citation></Reference><Reference><Citation>Dolezel P., Koudelkova P., Mlejnek P. Halogenation of N6-benzyladenosine decreases its cytotoxicity in human leukemia cells. Toxicol. In Vitro. 2010;24:2079&#x2013;2083. doi: 10.1016/j.tiv.2010.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tiv.2010.07.010</ArticleId><ArticleId IdType="pubmed">20637856</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A., Franco D., Tucker S., Hilgenfeld R., Froeyen M., Leyssen P., Neyts J. The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob. Agents Chemother. 2014;58:6990&#x2013;6992. doi: 10.1128/AAC.03328-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.03328-14</ArticleId><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>